MERSANA THERAPEUTICS INC (MRSN)
US59045L1061 - Common Stock
MERSANA THERAPEUTICS INC
NASDAQ:MRSN (7/3/2024, 7:22:11 PM)
1.84
-0.02 (-1.08%)
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2017-06-28. The firm is focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. The firm lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase I clinical trial evaluating UpRi in combination with carboplatin, and UP-NEXT, a Phase III clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Its pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139
P: 16174980020
CEO: Anna Protopapas
Employees: 228
Website: https://www.mersana.com/
MRSN News
20 days ago - ChartmillGet insights into the top gainers and losers of Friday's after-hours session.After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
a month ago - Mersana Therapeutics, Inc.Mersana Therapeutics to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
2 months ago - Market News VideoNotable Thursday Option Activity: PODD, BGS, MRSN2 months ago - InvestorPlaceMRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024MRSN stock results show that Mersana Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
2 months ago - Mersana Therapeutics, Inc.Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsCAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
2 months ago - Mersana Therapeutics, Inc.Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...
MRSN Twits
Here you can normally see the latest stock twits on MRSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
